Losartan in Special Populations: Transplant, HIV, Pediatric, and Other High-Risk Groups

How Losartan Works: Mechanism at the AT1 Receptor

Losartan selectively and competitively blocks the angiotensin II type 1 (AT1) receptor, preventing angiotensin II from binding and triggering vasoconstriction, aldosterone release, and sodium retention. Blood pressure falls, renal afferent arteriole tone decreases, and proteinuria is reduced. Unlike ACE inhibitors, losartan does not raise bradykinin, so cough and angioedema rates are substantially lower [1].

Parent Drug vs. Active Metabolite

After oral dosing, losartan is converted in the liver by CYP2C9 and CYP3A4 to EXP3174, its active 5-carboxylic acid metabolite [2]. EXP3174 is 10 to 40 times more pharmacologically potent than the parent compound and has a longer half-life of roughly 6 to 9 hours versus 2 hours for losartan itself. This conversion step is the single most clinically important pharmacokinetic fact about losartan: any drug or condition that impairs CYP2C9 activity will blunt the antihypertensive effect.

AT1 Blockade Downstream Effects

AT1 blockade reduces:

• Systemic vascular resistance (primary antihypertensive effect)
• Glomerular filtration pressure, slowing CKD progression in diabetic nephropathy [3]
• Cardiac preload and afterload, reducing left ventricular hypertrophy (LVH)
• Aldosterone secretion, lowering sodium retention and potassium excretion

The LIFE trial (N=9,193) showed that losartan 50 to 100 mg/day reduced the composite endpoint of cardiovascular death, stroke, and myocardial infarction by 13% compared with atenolol 50 to 100 mg/day over a mean of 4.8 years (RR 0.87, 95% CI 0.77 to 0.98, P=0.021) [4]. Regression of LVH was significantly greater in the losartan arm, which may account for part of the stroke reduction beyond blood pressure lowering alone.

Losartan in Transplant Recipients

Transplant recipients carry a disproportionate burden of hypertension, with reported prevalence of 70 to 90% post-kidney transplant and even higher rates after heart transplant. Losartan is often used in this setting, but two major issues shape its use: calcineurin inhibitor (CNI) interactions and post-transplant erythrocytosis.

Cyclosporine and Tacrolimus Interactions

Cyclosporine inhibits CYP3A4 and P-glycoprotein, raising losartan plasma concentrations by approximately 50 to 80% in some case series [5]. Tacrolimus similarly inhibits CYP3A4, though the magnitude is somewhat smaller. The practical result: patients on CNIs may achieve adequate blood pressure control at lower losartan doses, and the risk of hypotension on the standard 50 mg starting dose is real. Starting at 25 mg/day and titrating based on response is reasonable in this group.

Hyperkalemia Risk in Transplant

AT1 blockade reduces aldosterone, which already tends to be suppressed in patients on CNIs. Post-transplant patients also commonly have type IV renal tubular acidosis from CNI nephrotoxicity. Stacking an ARB onto a CNI-based regimen can push serum potassium to dangerous levels. A 2003 retrospective analysis found that ARB use in kidney transplant recipients raised mean serum potassium by 0.4 to 0.6 mEq/L compared to calcium channel blocker controls [6]. Serum potassium should be checked within 1 week of starting or up-titrating losartan in transplant patients.

Post-Transplant Erythrocytosis

Post-transplant erythrocytosis (PTE), defined as a hematocrit persistently above 51%, occurs in 8 to 15% of renal transplant recipients, typically within the first 2 years. ARBs, including losartan, reduce erythropoiesis by blocking AT1-mediated stimulation of erythropoietin production and by direct effects on erythroid progenitor cells [7]. Losartan 50 mg/day has been shown to normalize hematocrit in PTE within 3 months in small controlled trials, making it a preferred agent when both hypertension and PTE coexist.

Losartan in People Living with HIV

People living with HIV (PLWH) have a 50 to 75% higher risk of hypertension compared with HIV-negative controls, driven by antiretroviral toxicity, chronic inflammation, and immune activation [8]. Losartan is a reasonable ARB choice in this group, but protease inhibitors (PIs) complicate its use substantially.

Protease Inhibitor Drug Interactions

Ritonavir and cobicistat, used as pharmacokinetic boosters in most modern PI-based regimens, are potent CYP3A4 inhibitors. Because CYP3A4 converts losartan to EXP3174, ritonavir-boosted regimens reduce this conversion, lowering the concentration of the active metabolite while raising parent-drug concentrations. The net antihypertensive effect may be unpredictable. A 2015 pharmacokinetic study found that ritonavir 100 mg twice daily reduced EXP3174 AUC by approximately 30% while increasing losartan AUC by 62% [9]. Clinicians should monitor blood pressure carefully in PLWH starting or stopping PI-based regimens and consider alternative ARBs (such as valsartan, which is not CYP-metabolized to an active species) when tight pharmacokinetic predictability is needed.

Kidney Protection in HIV-Associated Nephropathy

HIV-associated nephropathy (HIVAN) is a collapsing focal segmental glomerulosclerosis that can progress rapidly to end-stage renal disease. Renin-angiotensin system blockade, including ARBs, is recommended in HIVAN to reduce proteinuria and slow GFR decline [10]. Losartan's proven antiproteinuric effect in diabetic nephropathy (RENAAL trial, N=1,513: 35% reduction in the composite of doubling serum creatinine, ESRD, or death vs. Placebo, P<0.001) [3] provides a pharmacological rationale for its use in HIVAN, even though HIVAN-specific ARB trials are small and largely observational.

Tenofovir and Additive Nephrotoxicity

Tenofovir disoproxil fumarate (TDF), still widely used globally, is nephrotoxic in a dose- and duration-dependent fashion. Adding losartan, which reduces intraglomerular pressure, could theoretically attenuate TDF-mediated glomerular hyperfiltration. Some nephrologists consider this a benefit; others worry that the combination may mask early TDF nephrotoxicity by lowering creatinine less than expected. Monitoring creatinine and urinary protein-to-creatinine ratio every 3 to 6 months is standard practice in PLWH on TDF plus any RAS blocker.

Losartan in Pediatric Patients

FDA-Approved Dosing in Children

The FDA approved losartan for pediatric hypertension in patients aged 6 years and older based on pharmacokinetic and efficacy data from studies conducted under the Pediatric Research Equity Act [11]. The recommended starting dose is 0.7 mg/kg/day orally, not to exceed 50 mg/day. Children weighing 20 to 50 kg may receive a maximum of 50 mg/day; those above 50 kg may be titrated to 100 mg/day. An oral suspension (2.5 mg/mL) is available for children who cannot swallow tablets.

Pharmacokinetics in Children

Clearance of losartan per kilogram body weight is approximately 2-fold higher in children than adults, meaning pediatric patients often need weight-adjusted doses at the higher end of the range to achieve comparable plasma concentrations [12]. The conversion ratio of losartan to EXP3174 is similar in children over 6 years to that in adults, so the CYP2C9 interaction considerations are identical.

Special Considerations: Alport Syndrome and CKD

Children with Alport syndrome, a hereditary nephropathy caused by mutations in type IV collagen genes, are frequently started on RAS blockade early to slow proteinuria progression. The 2013 European Alport Consortium consensus recommended ARBs as first-line therapy in proteinuric Alport syndrome, citing a median 10-year delay in ESRD onset with early RAS blockade [13]. Losartan is one of the most commonly used ARBs in this context, though head-to-head pediatric ARB trials are lacking.

Losartan in Hepatic Impairment

Losartan undergoes extensive first-pass hepatic metabolism. In patients with mild-to-moderate hepatic impairment (Child-Pugh A or B), plasma concentrations of both losartan and EXP3174 are markedly elevated. A pharmacokinetic study showed that patients with cirrhosis had a 5-fold increase in losartan AUC and a 1.7-fold increase in EXP3174 AUC compared with healthy controls [14]. The FDA label recommends starting at 25 mg/day in patients with a history of hepatic impairment [1]. Data in Child-Pugh C (severe) cirrhosis are limited, and losartan should generally be avoided or used only under specialist supervision in that setting.

Losartan in Elderly Patients

Blood pressure response to losartan in patients aged 65 and older is similar to that in younger adults, but age-related changes in renal function, volume status, and baroreceptor sensitivity increase the risk of hypotension and acute kidney injury. The LIFE trial enrolled patients up to age 80 and found comparable relative risk reductions across age groups, supporting efficacy in older adults [4]. Starting at 25 mg/day in frail elderly patients with eGFR <45 mL/min/1.73 m² or baseline systolic BP <150 mmHg reduces the risk of first-dose hypotension.

Losartan in Chronic Kidney Disease and Diabetic Nephropathy

The RENAAL trial (N=1,513, mean follow-up 3.4 years) is the landmark evidence base for losartan in diabetic nephropathy. Losartan 50 to 100 mg/day reduced the composite of doubling serum creatinine, ESRD, or all-cause death by 16% versus placebo (RR 0.84, 95% CI 0.72 to 0.98, P=0.022) [3]. The reduction in ESRD alone was 28% (P=0.002). These benefits were independent of the blood-pressure-lowering effect, confirming a direct renoprotective mechanism via reduced glomerular hypertension.

CKD Staging and Dose Considerations

No dose reduction is required for GFR-based CKD staging alone, because losartan is primarily hepatically cleared. Potassium monitoring, however, becomes critical as GFR falls below 45 mL/min/1.73 m². The 2022 KDIGO CKD guideline recommends RAS blockade in people with diabetes and CKD who have urine albumin-to-creatinine ratio above 300 mg/g, regardless of blood pressure level [15]. Losartan 100 mg/day is the dose most commonly used in CKD trials and is the appropriate target in proteinuric diabetic nephropathy.

Dual RAS Blockade: Avoid It

Combining losartan with an ACE inhibitor or with aliskiren does not improve renal outcomes and substantially raises risks of hyperkalemia, hypotension, and acute kidney injury. The ONTARGET trial (N=25,620) showed that telmisartan plus ramipril had significantly more adverse renal events than either drug alone [16]. This finding applies to all ARBs, including losartan. Dual RAS blockade is contraindicated in most guidelines.

Losartan in Pregnancy and Patients of Childbearing Potential

Losartan is contraindicated in the second and third trimesters of pregnancy. AT1 receptor blockade in the fetus causes fetal renal tubular dysplasia, oligohydramnios, limb contractures, craniofacial abnormalities, and neonatal anuria. The FDA labeling classifies losartan as Category D when used in the second and third trimesters, with risks analogous to Category X given the severity of fetal harm [1]. Women who become pregnant while taking losartan should discontinue it immediately and transition to methyldopa, labetalol, or nifedipine, which have established safety records in pregnancy [17].

First-trimester exposure carries a lower but still uncertain teratogenic risk. Patients planning pregnancy should be switched to a safer antihypertensive before attempting conception.

Losartan in Heart Failure

The ELITE II trial (N=3,152) compared losartan 50 mg/day with captopril 50 mg three times daily in elderly patients with symptomatic heart failure and ejection fraction below 40% [18]. All-cause mortality did not differ significantly between groups (RR 1.13, 95% CI 0.95 to 1.35, P=0.16). Losartan was better tolerated: only 9.7% of patients in the losartan arm discontinued due to adverse effects versus 14.7% in the captopril arm (P<0.001). Current 2022 AHA/ACC heart failure guidelines list ARBs as an acceptable alternative to ACE inhibitors in patients who cannot tolerate them due to cough or angioedema, with a Class I, Level A recommendation for guideline-directed medical therapy including RAS blockade [19].

Drug Interactions Across All Special Populations

The table below summarizes the most clinically consequential losartan drug interactions, organized by interaction mechanism, relevant special population, and recommended action.

| Interacting Drug | Mechanism | Population | Action | |---|---|---|---| | Cyclosporine | CYP3A4 inhibition, P-gp inhibition | Transplant | Start losartan 25 mg; monitor BP weekly | | Ritonavir / cobicistat | CYP3A4 inhibition | HIV | Expect reduced EXP3174; monitor BP; consider valsartan | | Fluconazole | CYP2C9 inhibition | Any | Reduces EXP3174 by ~40%; may blunt BP control | | NSAIDs | Prostaglandin inhibition | Elderly, CKD | Attenuates antihypertensive effect; raises AKI risk | | Potassium-sparing diuretics | Additive hyperkalemia | Transplant, CKD | Monitor K+ within 1 week; avoid in K+ >5.0 mEq/L | | ACE inhibitors / aliskiren | Dual RAS blockade | CKD, HF | Contraindicated; ONTARGET evidence | | Lithium | Reduced renal lithium clearance | Psychiatric patients | Monitor lithium levels; may need dose reduction |

Fluconazole deserves particular attention because it is widely used for fungal prophylaxis in transplant and HIV patients, the same populations where losartan dose titration is most complex. A crossover pharmacokinetic study showed fluconazole 200 mg/day reduced EXP3174 AUC by 44% and increased losartan AUC by 69% [2]. The net antihypertensive effect diminished significantly in some subjects. Clinicians should recheck blood pressure within 5 to 7 days of starting or stopping fluconazole in a patient on losartan.

Monitoring Parameters by Population

Standard monitoring for all patients on losartan includes serum creatinine, electrolytes (especially potassium), and blood pressure at baseline, at 1 to 2 weeks after starting or up-titrating, and then every 3 to 6 months. Population-specific additions:

• Transplant: weekly potassium for the first month; hematocrit at 3 months if PTE suspected
• HIV on PI-based ART: blood pressure check within 1 week of any ART regimen change
• Pediatric CKD: urine protein-to-creatinine ratio every 3 months; height velocity annually
• Hepatic impairment: liver function tests every 3 months; titrate slowly
• Elderly, eGFR <45: serum creatinine and potassium at 1 week after any dose change